摘要
目的探究血管靶向药联合化疗治疗中晚期肝癌的临床效果。方法选取2019年4月至2021年1月136例中晚期肝癌患者作为研究对象,随机将其分为对照组和观察组,各68例。对照组采用化疗治疗,观察组在对照组的基础上联合血管靶向药治疗。比较两组的治疗效果。结果治疗前,两组的甲胎蛋白(AFP)、甲胎蛋白异质体(AFP-L3)、高尔基体蛋白73(GP73)水平比较,差异无统计学意义(P>0.05);治疗后3个月,两组的AFP、AFP-L3、GP73水平均低于治疗前,且观察组低于对照组,差异具有统计学意义(P<0.05)。治疗前,两组的白细胞介素-2(IL-2)、肿瘤坏死因子-α(TNF-α)、白细胞介素-4(IL-4)、白细胞介素-6(IL-6)及白细胞介素-10(IL-10)水平比较,差异无统计学意义(P>0.05);治疗后3个月,两组的IL-2、TNF-α、IL-6水平低于治疗前,IL-4、IL-10水平高于治疗前,且观察组优于对照组,差异具有统计学意义(P<0.05)。两组的毒副反应总发生率比较,差异无统计学意义(P>0.05)。结论血管靶向药物联合化疗治疗中晚期肝癌患者的安全性较高,可降低肿瘤标志物水平,改善辅助性T细胞1(Th1)、辅助性T细胞2(Th2)因子水平,调节机体免疫功能,巩固化疗效果,值得临床推广与应用。
Objective To investigate the clinical effect of vascular targeting drugs combined with chemotherapy in the treatment of advanced liver cancer.Methods A total of 136 patients with advanced liver cancer from April 2019 to January2021 were selected as the research objects and randomly divided into control group and observation group,with 68 cases in each group.The control group was treated with chemotherapy,and the observation group was treated with vascular targeting drugs based on the control group.The therapeutic effects of the two groups were compared.Results Before treatment,there were no significant differences in the levels of alpha fetoprotein(AFP),alpha fetoprotein-L3(AFP-L3)and Golgi protein 73(GP73)between the two groups(P>0.05);after 3 months of treatment,the levels of AFP,AFP-L3 and GP73 in both groups were lower than those before treatment,those in the observation group were lower than the control group,and the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in the levels of interleukin-2(IL-2),tumor necrosis factor-α(TNF-α),interleukin-4(IL-4),interleukin-6(IL-6)and interleukin-10(IL-10)between the two groups(P>0.05);after 3 months of treatment,the levels of IL-2,TNF-αand IL-6 in both groups were lower than those before treatment,the levels of IL-4 and IL-10 were higher than those before treatment,those in the observation group were better than the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of toxicity and side effects between the two groups(P>0.05).Conclusion Vascular targeted drugs combined with chemotherapy in the treatment of patients with advanced liver cancer has high safety,it can reduce the levels of tumor markers,improve the levels of helper T cell 1(Th1)and helper T cell 2(Th2)factors,regulate the immune function of the body,and consolidate the effect of chemotherapy,which is worthy of clinical promotion and application.
作者
范斌
张云翼
李霞
FAN Bin;ZHANG Yunyi;LI Xia(the First Affiliated Hospital of Northwest University/Xi'an No.1 Hospital,Xi'an 710002;Public Health and Management School,Ningxia Medical University,Yinchuan 750004,China)
出处
《临床医学研究与实践》
2023年第3期28-31,共4页
Clinical Research and Practice
